SK282457B6 - [1,2,4]Triazolo[4,3-a]chinoxalinónové zlúčeniny, farmaceutický prostriedok, spôsob prípravy [1,2,4]triazolo[4,3-a]chinoxalinónových zlúčenín a ich použitie - Google Patents
[1,2,4]Triazolo[4,3-a]chinoxalinónové zlúčeniny, farmaceutický prostriedok, spôsob prípravy [1,2,4]triazolo[4,3-a]chinoxalinónových zlúčenín a ich použitie Download PDFInfo
- Publication number
- SK282457B6 SK282457B6 SK334-97A SK33497A SK282457B6 SK 282457 B6 SK282457 B6 SK 282457B6 SK 33497 A SK33497 A SK 33497A SK 282457 B6 SK282457 B6 SK 282457B6
- Authority
- SK
- Slovakia
- Prior art keywords
- compound
- formula
- triazolo
- defined above
- alkoxy
- Prior art date
Links
- NBXOKUUXBOFVIJ-UHFFFAOYSA-N 2h-[1,2,4]triazolo[4,3-a]quinoxalin-1-one Chemical class C1=CC=C2N3C(=O)NN=C3C=NC2=C1 NBXOKUUXBOFVIJ-UHFFFAOYSA-N 0.000 title claims abstract description 8
- 238000002360 preparation method Methods 0.000 title claims description 8
- 239000000825 pharmaceutical preparation Substances 0.000 title description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 24
- 125000003545 alkoxy group Chemical group 0.000 claims abstract description 22
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 21
- 239000001257 hydrogen Substances 0.000 claims abstract description 21
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 14
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 14
- 125000002883 imidazolyl group Chemical group 0.000 claims abstract description 10
- 208000013403 hyperactivity Diseases 0.000 claims abstract description 8
- 230000002964 excitative effect Effects 0.000 claims abstract description 7
- 239000002858 neurotransmitter agent Substances 0.000 claims abstract description 6
- 229910052736 halogen Inorganic materials 0.000 claims abstract description 5
- 150000002367 halogens Chemical class 0.000 claims abstract description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 5
- 125000001425 triazolyl group Chemical group 0.000 claims abstract description 5
- 150000001875 compounds Chemical class 0.000 claims description 116
- -1 [1,2,4] Triazolo [4,3-a] quinoxalinone compound Chemical class 0.000 claims description 34
- 150000003839 salts Chemical class 0.000 claims description 17
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims description 8
- 239000000460 chlorine Substances 0.000 claims description 8
- 229910052801 chlorine Inorganic materials 0.000 claims description 8
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 8
- 238000007363 ring formation reaction Methods 0.000 claims description 8
- 229910052794 bromium Inorganic materials 0.000 claims description 7
- 150000002431 hydrogen Chemical class 0.000 claims description 7
- 229910052740 iodine Inorganic materials 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- 230000007062 hydrolysis Effects 0.000 claims description 6
- 238000006460 hydrolysis reaction Methods 0.000 claims description 6
- 201000006474 Brain Ischemia Diseases 0.000 claims description 5
- 206010008120 Cerebral ischaemia Diseases 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 5
- 206010008118 cerebral infarction Diseases 0.000 claims description 5
- 239000003085 diluting agent Substances 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 claims description 5
- 229910004013 NO 2 Inorganic materials 0.000 claims description 4
- 238000006392 deoxygenation reaction Methods 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- RWINCEIKIGJVFE-UHFFFAOYSA-N CCOC(=P(O)=O)C1=NN=C(C(NC2=CC=3C(F)(F)F)=O)N1C2=CC=3N1C=CN=C1 Chemical compound CCOC(=P(O)=O)C1=NN=C(C(NC2=CC=3C(F)(F)F)=O)N1C2=CC=3N1C=CN=C1 RWINCEIKIGJVFE-UHFFFAOYSA-N 0.000 claims description 3
- RVFUUIZPAHUNPZ-UHFFFAOYSA-N [4-oxo-8-(2-propan-2-ylimidazol-1-yl)-7-(trifluoromethyl)-5h-[1,2,4]triazolo[4,3-a]quinoxalin-1-yl]methylphosphonic acid Chemical compound CC(C)C1=NC=CN1C1=CC(N2C(CP(O)(O)=O)=NN=C2C(=O)N2)=C2C=C1C(F)(F)F RVFUUIZPAHUNPZ-UHFFFAOYSA-N 0.000 claims description 3
- 230000002140 halogenating effect Effects 0.000 claims description 3
- 238000005984 hydrogenation reaction Methods 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- GUGQQGROXHPINL-UHFFFAOYSA-N 2-oxobutanoyl chloride Chemical compound CCC(=O)C(Cl)=O GUGQQGROXHPINL-UHFFFAOYSA-N 0.000 claims description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 2
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 claims description 2
- 239000012346 acetyl chloride Substances 0.000 claims description 2
- 150000001263 acyl chlorides Chemical class 0.000 claims description 2
- 230000010933 acylation Effects 0.000 claims description 2
- 238000005917 acylation reaction Methods 0.000 claims description 2
- 230000002152 alkylating effect Effects 0.000 claims description 2
- 238000006243 chemical reaction Methods 0.000 claims description 2
- 238000007327 hydrogenolysis reaction Methods 0.000 claims description 2
- 238000006467 substitution reaction Methods 0.000 claims description 2
- 230000003301 hydrolyzing effect Effects 0.000 claims 2
- 230000026030 halogenation Effects 0.000 claims 1
- 238000005658 halogenation reaction Methods 0.000 claims 1
- 239000000243 solution Substances 0.000 description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- 239000005557 antagonist Substances 0.000 description 11
- 102000005962 receptors Human genes 0.000 description 11
- 108020003175 receptors Proteins 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 238000005160 1H NMR spectroscopy Methods 0.000 description 10
- JSFLFNPZGIDUBV-UHFFFAOYSA-N 3-(2-amino-3-hydroxy-5-methyl-3h-1,2-oxazol-4-yl)propanoic acid Chemical compound CC1=C(CCC(O)=O)C(O)N(N)O1 JSFLFNPZGIDUBV-UHFFFAOYSA-N 0.000 description 10
- 102000003678 AMPA Receptors Human genes 0.000 description 10
- 108090000078 AMPA Receptors Proteins 0.000 description 10
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 10
- 238000001914 filtration Methods 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 239000000203 mixture Substances 0.000 description 9
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 8
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 7
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 229910052783 alkali metal Inorganic materials 0.000 description 6
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 6
- 238000009739 binding Methods 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 5
- ZTPNVPPLIDWEGE-UHFFFAOYSA-N P.S.S Chemical compound P.S.S ZTPNVPPLIDWEGE-UHFFFAOYSA-N 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 150000001340 alkali metals Chemical class 0.000 description 5
- 230000027455 binding Effects 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 229960002989 glutamic acid Drugs 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- 241000287828 Gallus gallus Species 0.000 description 4
- 102000000079 Kainic Acid Receptors Human genes 0.000 description 4
- 108010069902 Kainic Acid Receptors Proteins 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 230000003042 antagnostic effect Effects 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 210000003169 central nervous system Anatomy 0.000 description 4
- 235000013330 chicken meat Nutrition 0.000 description 4
- 230000002461 excitatory amino acid Effects 0.000 description 4
- 239000003257 excitatory amino acid Substances 0.000 description 4
- VLSMHEGGTFMBBZ-OOZYFLPDSA-N kainic acid Chemical compound CC(=C)[C@H]1CN[C@H](C(O)=O)[C@H]1CC(O)=O VLSMHEGGTFMBBZ-OOZYFLPDSA-N 0.000 description 4
- 239000011777 magnesium Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 102000018899 Glutamate Receptors Human genes 0.000 description 3
- 108010027915 Glutamate Receptors Proteins 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 208000002740 Muscle Rigidity Diseases 0.000 description 3
- 208000028017 Psychotic disease Diseases 0.000 description 3
- ASNFTDCKZKHJSW-REOHCLBHSA-N Quisqualic acid Chemical compound OC(=O)[C@@H](N)CN1OC(=O)NC1=O ASNFTDCKZKHJSW-REOHCLBHSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 206010047700 Vomiting Diseases 0.000 description 3
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 3
- VLSMHEGGTFMBBZ-UHFFFAOYSA-N alpha-Kainic acid Natural products CC(=C)C1CNC(C(O)=O)C1CC(O)=O VLSMHEGGTFMBBZ-UHFFFAOYSA-N 0.000 description 3
- 230000036592 analgesia Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- HERPVHLYIHBEFW-ZETCQYMHSA-N diethyl (2s)-2-aminopentanedioate Chemical compound CCOC(=O)CC[C@H](N)C(=O)OCC HERPVHLYIHBEFW-ZETCQYMHSA-N 0.000 description 3
- 206010015037 epilepsy Diseases 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 208000028867 ischemia Diseases 0.000 description 3
- 229950006874 kainic acid Drugs 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 150000003852 triazoles Chemical group 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- FFFOAMJUKIHHDL-UHFFFAOYSA-N 2-diethoxyphosphoryl-n'-[3-oxo-4-phenylmethoxy-7-(2-propan-2-ylimidazol-1-yl)-6-(trifluoromethyl)quinoxalin-2-yl]acetohydrazide Chemical compound O=C1C(NNC(=O)CP(=O)(OCC)OCC)=NC2=CC(N3C(=NC=C3)C(C)C)=C(C(F)(F)F)C=C2N1OCC1=CC=CC=C1 FFFOAMJUKIHHDL-UHFFFAOYSA-N 0.000 description 2
- CLAKAYYJMKYMRC-UHFFFAOYSA-N 2-diethoxyphosphorylacetyl chloride Chemical compound CCOP(=O)(CC(Cl)=O)OCC CLAKAYYJMKYMRC-UHFFFAOYSA-N 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- MVNIKDQJNORHOT-UHFFFAOYSA-N CCOC(=P(O)=O)C1=NN=C(C(NC2=CC=3C(F)(F)F)=O)N1C2=CC=3N1C=CN=C1C(C)C Chemical compound CCOC(=P(O)=O)C1=NN=C(C(NC2=CC=3C(F)(F)F)=O)N1C2=CC=3N1C=CN=C1C(C)C MVNIKDQJNORHOT-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical group [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 2
- ASNFTDCKZKHJSW-UHFFFAOYSA-N DL-Quisqualic acid Natural products OC(=O)C(N)CN1OC(=O)NC1=O ASNFTDCKZKHJSW-UHFFFAOYSA-N 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 208000023105 Huntington disease Diseases 0.000 description 2
- 208000013016 Hypoglycemia Diseases 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- ZXEUYVUQBCVOPG-UHFFFAOYSA-N O=C1NC2=CC=CC=C2N2C(N3N=CN=C3)=NN=C12 Chemical compound O=C1NC2=CC=CC=C2N2C(N3N=CN=C3)=NN=C12 ZXEUYVUQBCVOPG-UHFFFAOYSA-N 0.000 description 2
- MHIBJAJDQXSSLK-UHFFFAOYSA-N [8-imidazol-1-yl-4-oxo-7-(trifluoromethyl)-5h-[1,2,4]triazolo[4,3-a]quinoxalin-1-yl]methylphosphonic acid Chemical compound OP(O)(=O)CC1=NN=C(C(NC2=CC=3C(F)(F)F)=O)N1C2=CC=3N1C=CN=C1 MHIBJAJDQXSSLK-UHFFFAOYSA-N 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000008485 antagonism Effects 0.000 description 2
- 229960005261 aspartic acid Drugs 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- IYYIVELXUANFED-UHFFFAOYSA-N bromo(trimethyl)silane Chemical compound C[Si](C)(C)Br IYYIVELXUANFED-UHFFFAOYSA-N 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 125000000717 hydrazino group Chemical group [H]N([*])N([H])[H] 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 201000010901 lateral sclerosis Diseases 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- 208000005264 motor neuron disease Diseases 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 230000001722 neurochemical effect Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 230000009871 nonspecific binding Effects 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 210000001525 retina Anatomy 0.000 description 2
- 230000002207 retinal effect Effects 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 210000000278 spinal cord Anatomy 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- GMKMEZVLHJARHF-UHFFFAOYSA-N (2R,6R)-form-2.6-Diaminoheptanedioic acid Natural products OC(=O)C(N)CCCC(N)C(O)=O GMKMEZVLHJARHF-UHFFFAOYSA-N 0.000 description 1
- IRJCBFDCFXCWGO-SCSAIBSYSA-N (2r)-2-azaniumyl-2-(3-oxo-1,2-oxazol-5-yl)acetate Chemical compound [O-]C(=O)[C@H]([NH3+])C1=CC(=O)NO1 IRJCBFDCFXCWGO-SCSAIBSYSA-N 0.000 description 1
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
- GDQULGSFMNJDMO-UHFFFAOYSA-N (8-chloro-7-imidazol-1-yl-4-oxo-5h-[1,2,4]triazolo[4,3-a]quinoxalin-1-yl)methylphosphonic acid Chemical compound OP(O)(=O)CC1=NN=C(C(NC2=C3)=O)N1C2=CC(Cl)=C3N1C=CN=C1 GDQULGSFMNJDMO-UHFFFAOYSA-N 0.000 description 1
- RYZVHTWWIXFYSH-UHFFFAOYSA-N (8-cyano-7-imidazol-1-yl-4-oxo-5h-[1,2,4]triazolo[4,3-a]quinoxalin-1-yl)methylphosphonic acid Chemical compound OP(O)(=O)CC1=NN=C(C(NC2=C3)=O)N1C2=CC(C#N)=C3N1C=CN=C1 RYZVHTWWIXFYSH-UHFFFAOYSA-N 0.000 description 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- 125000003626 1,2,4-triazol-1-yl group Chemical group [*]N1N=C([H])N=C1[H] 0.000 description 1
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical class OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
- APICWTYZEDXBFT-UHFFFAOYSA-N 1-[7-imidazol-1-yl-4-oxo-8-(trifluoromethyl)-5h-[1,2,4]triazolo[4,3-a]quinoxalin-1-yl]ethylphosphonic acid Chemical compound OP(=O)(O)C(C)C1=NN=C(C(NC2=C3)=O)N1C2=CC(C(F)(F)F)=C3N1C=CN=C1 APICWTYZEDXBFT-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- KVVJCYJPFQKFEX-UHFFFAOYSA-N 2-diethoxyphosphoryl-n'-[4-hydroxy-7-imidazol-1-yl-3-oxo-6-(trifluoromethyl)quinoxalin-2-yl]acetohydrazide Chemical compound FC(F)(F)C=1C=C2N(O)C(=O)C(NNC(=O)CP(=O)(OCC)OCC)=NC2=CC=1N1C=CN=C1 KVVJCYJPFQKFEX-UHFFFAOYSA-N 0.000 description 1
- FMMZPBSMWMNHLE-UHFFFAOYSA-N 2-diethoxyphosphoryl-n'-[7-imidazol-1-yl-3-oxo-4-phenylmethoxy-6-(trifluoromethyl)quinoxalin-2-yl]acetohydrazide Chemical compound O=C1C(NNC(=O)CP(=O)(OCC)OCC)=NC2=CC(N3C=NC=C3)=C(C(F)(F)F)C=C2N1OCC1=CC=CC=C1 FMMZPBSMWMNHLE-UHFFFAOYSA-N 0.000 description 1
- JRTNLUWVHJAZOX-UHFFFAOYSA-N 3-chloro-1-phenylmethoxy-6-(2-propan-2-ylimidazol-1-yl)-7-(trifluoromethyl)quinoxalin-2-one Chemical compound CC(C)C1=NC=CN1C(C(=C1)C(F)(F)F)=CC2=C1N(OCC=1C=CC=CC=1)C(=O)C(Cl)=N2 JRTNLUWVHJAZOX-UHFFFAOYSA-N 0.000 description 1
- BKVXBQHROCJTBV-UHFFFAOYSA-N 3-hydrazinyl-1-phenylmethoxy-6-(2-propan-2-ylimidazol-1-yl)-7-(trifluoromethyl)quinoxalin-2-one Chemical compound CC(C)C1=NC=CN1C(C(=C1)C(F)(F)F)=CC2=C1N(OCC=1C=CC=CC=1)C(=O)C(NN)=N2 BKVXBQHROCJTBV-UHFFFAOYSA-N 0.000 description 1
- UFWNWSNNBKAVIT-UHFFFAOYSA-N 3-hydrazinyl-6-imidazol-1-yl-1-phenylmethoxy-7-(trifluoromethyl)quinoxalin-2-one Chemical compound O=C1C(NN)=NC2=CC(N3C=NC=C3)=C(C(F)(F)F)C=C2N1OCC1=CC=CC=C1 UFWNWSNNBKAVIT-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- HQLMRIQTURZUHA-UHFFFAOYSA-N 4-phenylmethoxy-7-(2-propan-2-ylimidazol-1-yl)-6-(trifluoromethyl)-1h-quinoxaline-2,3-dione Chemical compound CC(C)C1=NC=CN1C(C(=C1)C(F)(F)F)=CC2=C1N(OCC=1C=CC=CC=1)C(=O)C(=O)N2 HQLMRIQTURZUHA-UHFFFAOYSA-N 0.000 description 1
- VOROEQBFPPIACJ-UHFFFAOYSA-N 5-Phosphononorvaline Chemical compound OC(=O)C(N)CCCP(O)(O)=O VOROEQBFPPIACJ-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 229910002012 Aerosil® Inorganic materials 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 102000015404 Amino Acid Receptors Human genes 0.000 description 1
- 108010025177 Amino Acid Receptors Proteins 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 208000002381 Brain Hypoxia Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- UYDFHPMBLODSKE-UHFFFAOYSA-N C(#N)C=1C=C2NC(C=3N(C2=CC1N1C(=NC=C1)C1=CC=CC=C1)C(=NN3)CP(=O)(O)O)=O Chemical compound C(#N)C=1C=C2NC(C=3N(C2=CC1N1C(=NC=C1)C1=CC=CC=C1)C(=NN3)CP(=O)(O)O)=O UYDFHPMBLODSKE-UHFFFAOYSA-N 0.000 description 1
- BWYPKSBRWXEPJQ-UHFFFAOYSA-N C(#N)C=1C=C2NC(C=3N(C2=CC1N1C=NC=C1)C(=NN3)CP(=O)(O)O)=O Chemical compound C(#N)C=1C=C2NC(C=3N(C2=CC1N1C=NC=C1)C(=NN3)CP(=O)(O)O)=O BWYPKSBRWXEPJQ-UHFFFAOYSA-N 0.000 description 1
- MMQMTRIWZAQVET-UHFFFAOYSA-N C(#N)C=1C=C2NC(C=3N(C2=CC=1N1C(=NC=C1)CC)C(=NN=3)CP(=O)(O)O)=O Chemical compound C(#N)C=1C=C2NC(C=3N(C2=CC=1N1C(=NC=C1)CC)C(=NN=3)CP(=O)(O)O)=O MMQMTRIWZAQVET-UHFFFAOYSA-N 0.000 description 1
- GBNQWANKSGDZKT-UHFFFAOYSA-N CC=1N(C=CN=1)C1=C(C=C2NC(C=3N(C2=C1)C(=NN=3)CP(=O)(O)O)=O)[N+](=O)[O-] Chemical compound CC=1N(C=CN=1)C1=C(C=C2NC(C=3N(C2=C1)C(=NN=3)CP(=O)(O)O)=O)[N+](=O)[O-] GBNQWANKSGDZKT-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- BTMJSUOVYABBHL-UHFFFAOYSA-N ClC=1C=C2NC(C=3N(C2=CC1N1C=NC=C1)C(=NN3)CP(=O)(O)O)=O Chemical compound ClC=1C=C2NC(C=3N(C2=CC1N1C=NC=C1)C(=NN3)CP(=O)(O)O)=O BTMJSUOVYABBHL-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- OYIFNHCXNCRBQI-SCSAIBSYSA-N D-2-aminoadipic acid Chemical compound OC(=O)[C@H](N)CCCC(O)=O OYIFNHCXNCRBQI-SCSAIBSYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-GSVOUGTGSA-N D-glutamic acid Chemical compound OC(=O)[C@H](N)CCC(O)=O WHUUTDBJXJRKMK-GSVOUGTGSA-N 0.000 description 1
- 229930182847 D-glutamic acid Natural products 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 229940123511 Excitatory amino acid receptor antagonist Drugs 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 241000699694 Gerbillinae Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010019196 Head injury Diseases 0.000 description 1
- IRJCBFDCFXCWGO-UHFFFAOYSA-N Ibotenic acid Natural products OC(=O)C(N)C1=CC(=O)NO1 IRJCBFDCFXCWGO-UHFFFAOYSA-N 0.000 description 1
- VBOQYPQEPHKASR-VKHMYHEASA-N L-homocysteic acid Chemical compound OC(=O)[C@@H](N)CCS(O)(=O)=O VBOQYPQEPHKASR-VKHMYHEASA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 1
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 1
- OKFRZUYBKPMIDW-UHFFFAOYSA-N N1(C=NC=C1)C1=C(C=C2NC(C=3N(C2=C1)C(=NN=3)CP(=O)(O)O)=O)[N+](=O)[O-] Chemical compound N1(C=NC=C1)C1=C(C=C2NC(C=3N(C2=C1)C(=NN=3)CP(=O)(O)O)=O)[N+](=O)[O-] OKFRZUYBKPMIDW-UHFFFAOYSA-N 0.000 description 1
- SOBUKKWVHHYEGW-UHFFFAOYSA-N N1(C=NC=C1)C=1C=C2NC(C=3N(C2=CC=1[N+](=O)[O-])C(=NN=3)CP(=O)(O)O)=O Chemical compound N1(C=NC=C1)C=1C=C2NC(C=3N(C2=CC=1[N+](=O)[O-])C(=NN=3)CP(=O)(O)O)=O SOBUKKWVHHYEGW-UHFFFAOYSA-N 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 208000027089 Parkinsonian disease Diseases 0.000 description 1
- 206010034010 Parkinsonism Diseases 0.000 description 1
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 1
- 230000010799 Receptor Interactions Effects 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- MYAGEVWLEZGXEM-UHFFFAOYSA-N [4-oxo-8-(1,2,4-triazol-1-yl)-7-(trifluoromethyl)-5h-[1,2,4]triazolo[4,3-a]quinoxalin-1-yl]methylphosphonic acid Chemical compound OP(O)(=O)CC1=NN=C(C(NC2=CC=3C(F)(F)F)=O)N1C2=CC=3N1C=NC=N1 MYAGEVWLEZGXEM-UHFFFAOYSA-N 0.000 description 1
- WXAXVWCOYUSLRN-UHFFFAOYSA-N [4-oxo-8-(2-phenylimidazol-1-yl)-7-(trifluoromethyl)-5h-[1,2,4]triazolo[4,3-a]quinoxalin-1-yl]methylphosphonic acid Chemical compound OP(O)(=O)CC1=NN=C(C(NC2=CC=3C(F)(F)F)=O)N1C2=CC=3N1C=CN=C1C1=CC=CC=C1 WXAXVWCOYUSLRN-UHFFFAOYSA-N 0.000 description 1
- RHDXPHOPKODHMS-UHFFFAOYSA-N [7-(2-methylimidazol-1-yl)-4-oxo-8-(trifluoromethyl)-5h-[1,2,4]triazolo[4,3-a]quinoxalin-1-yl]methylphosphonic acid Chemical compound CC1=NC=CN1C(C(=C1)C(F)(F)F)=CC2=C1N1C(CP(O)(O)=O)=NN=C1C(=O)N2 RHDXPHOPKODHMS-UHFFFAOYSA-N 0.000 description 1
- GRELPJYKWVEKRP-UHFFFAOYSA-N [7-cyano-4-oxo-8-(2-propan-2-ylimidazol-1-yl)-5H-[1,2,4]triazolo[4,3-a]quinoxalin-1-yl]methylphosphonic acid Chemical compound CC(C)C1=NC=CN1C1=CC(N2C(CP(O)(O)=O)=NN=C2C(=O)N2)=C2C=C1C#N GRELPJYKWVEKRP-UHFFFAOYSA-N 0.000 description 1
- KUGMVRBZHGAPJR-UHFFFAOYSA-N [7-cyano-4-oxo-8-(2-propylimidazol-1-yl)-5h-[1,2,4]triazolo[4,3-a]quinoxalin-1-yl]methylphosphonic acid Chemical compound CCCC1=NC=CN1C1=CC(N2C(CP(O)(O)=O)=NN=C2C(=O)N2)=C2C=C1C#N KUGMVRBZHGAPJR-UHFFFAOYSA-N 0.000 description 1
- QZWNSHYSEBCSHL-UHFFFAOYSA-N [7-cyano-4-oxo-8-(4-phenylimidazol-1-yl)-5h-[1,2,4]triazolo[4,3-a]quinoxalin-1-yl]methylphosphonic acid Chemical compound OP(O)(=O)CC1=NN=C(C(NC2=CC=3C#N)=O)N1C2=CC=3N(C=1)C=NC=1C1=CC=CC=C1 QZWNSHYSEBCSHL-UHFFFAOYSA-N 0.000 description 1
- DFWVHSXXQPFDMZ-UHFFFAOYSA-N [7-cyano-8-(2-methylimidazol-1-yl)-4-oxo-5h-[1,2,4]triazolo[4,3-a]quinoxalin-1-yl]methylphosphonic acid Chemical compound CC1=NC=CN1C1=CC(N2C(CP(O)(O)=O)=NN=C2C(=O)N2)=C2C=C1C#N DFWVHSXXQPFDMZ-UHFFFAOYSA-N 0.000 description 1
- IEMIBCLLLCWVMY-UHFFFAOYSA-N [7-cyano-8-(4-methylimidazol-1-yl)-4-oxo-5h-[1,2,4]triazolo[4,3-a]quinoxalin-1-yl]methylphosphonic acid Chemical compound C1=NC(C)=CN1C1=CC(N2C(CP(O)(O)=O)=NN=C2C(=O)N2)=C2C=C1C#N IEMIBCLLLCWVMY-UHFFFAOYSA-N 0.000 description 1
- AMJXQSBCRBCLLW-UHFFFAOYSA-N [7-imidazol-1-yl-4-oxo-8-(trifluoromethyl)-5h-[1,2,4]triazolo[4,3-a]quinoxalin-1-yl]methylphosphonic acid Chemical compound OP(O)(=O)CC1=NN=C(C(NC2=C3)=O)N1C2=CC(C(F)(F)F)=C3N1C=CN=C1 AMJXQSBCRBCLLW-UHFFFAOYSA-N 0.000 description 1
- WFUSZTFABCDRMD-UHFFFAOYSA-N [8-(2-methylimidazol-1-yl)-4-oxo-7-(trifluoromethyl)-5h-[1,2,4]triazolo[4,3-a]quinoxalin-1-yl]methylphosphonic acid Chemical compound CC1=NC=CN1C1=CC(N2C(CP(O)(O)=O)=NN=C2C(=O)N2)=C2C=C1C(F)(F)F WFUSZTFABCDRMD-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 239000003194 amino acid receptor blocking agent Substances 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 150000001991 dicarboxylic acids Chemical class 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000019961 diglycerides of fatty acid Nutrition 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- SRCZQMGIVIYBBJ-UHFFFAOYSA-N ethoxyethane;ethyl acetate Chemical compound CCOCC.CCOC(C)=O SRCZQMGIVIYBBJ-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940049906 glutamate Drugs 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 150000002391 heterocyclic compounds Chemical class 0.000 description 1
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 239000002555 ionophore Substances 0.000 description 1
- 230000000236 ionophoric effect Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- GMKMEZVLHJARHF-SYDPRGILSA-N meso-2,6-diaminopimelic acid Chemical compound [O-]C(=O)[C@@H]([NH3+])CCC[C@@H]([NH3+])C([O-])=O GMKMEZVLHJARHF-SYDPRGILSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 235000019960 monoglycerides of fatty acid Nutrition 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000016273 neuron death Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- XJLSEXAGTJCILF-UHFFFAOYSA-N nipecotic acid Chemical compound OC(=O)C1CCCNC1 XJLSEXAGTJCILF-UHFFFAOYSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- ZNNZYHKDIALBAK-UHFFFAOYSA-M potassium thiocyanate Chemical compound [K+].[S-]C#N ZNNZYHKDIALBAK-UHFFFAOYSA-M 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- FFRYUAVNPBUEIC-UHFFFAOYSA-N quinoxalin-2-ol Chemical class C1=CC=CC2=NC(O)=CN=C21 FFRYUAVNPBUEIC-UHFFFAOYSA-N 0.000 description 1
- 239000002287 radioligand Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000010410 reperfusion Effects 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000009291 secondary effect Effects 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000009782 synaptic response Effects 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Otolaryngology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DK106694 | 1994-09-16 | ||
| PCT/DK1995/000365 WO1996008493A1 (fr) | 1994-09-16 | 1995-09-12 | Derives de la [1,2,4]triazolo[4,3-a]quinoxalinone, leur preparation et utilisation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| SK33497A3 SK33497A3 (en) | 1998-02-04 |
| SK282457B6 true SK282457B6 (sk) | 2002-02-05 |
Family
ID=8100607
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK334-97A SK282457B6 (sk) | 1994-09-16 | 1995-09-12 | [1,2,4]Triazolo[4,3-a]chinoxalinónové zlúčeniny, farmaceutický prostriedok, spôsob prípravy [1,2,4]triazolo[4,3-a]chinoxalinónových zlúčenín a ich použitie |
Country Status (22)
| Country | Link |
|---|---|
| EP (1) | EP0781282B1 (fr) |
| JP (1) | JPH10506620A (fr) |
| KR (1) | KR970706285A (fr) |
| CN (1) | CN1193973A (fr) |
| AT (1) | ATE183186T1 (fr) |
| AU (1) | AU694554B2 (fr) |
| CA (1) | CA2200056A1 (fr) |
| CZ (1) | CZ284930B6 (fr) |
| DE (1) | DE69511420T2 (fr) |
| DK (1) | DK0781282T3 (fr) |
| ES (1) | ES2138233T3 (fr) |
| FI (1) | FI971076A (fr) |
| GR (1) | GR3031788T3 (fr) |
| HU (1) | HUT76802A (fr) |
| IL (1) | IL115299A0 (fr) |
| NO (1) | NO308797B1 (fr) |
| NZ (1) | NZ292108A (fr) |
| PL (1) | PL319175A1 (fr) |
| SK (1) | SK282457B6 (fr) |
| TW (1) | TW397835B (fr) |
| WO (1) | WO1996008493A1 (fr) |
| ZA (1) | ZA957794B (fr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL125950A0 (en) * | 1997-09-05 | 1999-04-11 | Pfizer Prod Inc | Methods of administering ampa receptor antagonists to treat dyskinesias associated with dopamine agonist therapy |
| BR9814628A (pt) | 1997-11-11 | 2001-11-27 | Ono Pharmaceutical Co | Derivados de pirazina fundidos |
| MX2011009314A (es) | 2009-03-05 | 2011-10-11 | Astellas Pharma Inc | Compuesto de quinoxalina. |
| PT2615096T (pt) | 2010-09-07 | 2019-10-15 | Astellas Pharma Inc | Composto de quinoxalina |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4354027A (en) * | 1980-05-19 | 1982-10-12 | Usv Pharmaceutical Corporation | Triazoloquinoxalin-4-ones |
| US5153196A (en) * | 1991-06-05 | 1992-10-06 | Eli Lilly And Company | Excitatory amino acid receptor antagonists and methods for the use thereof |
| DK162491D0 (da) * | 1991-09-20 | 1991-09-20 | Novo Nordisk As | Heterocycliske forbindelser, deres fremstilling og farmaceutiske praeparater indeholdende forbindelserne |
| AU3767793A (en) * | 1992-04-03 | 1993-11-08 | Yamanouchi Pharmaceutical Co., Ltd. | Fused quinoxalinone derivative and pharmaceutical composition containing the same |
| DK31093D0 (fr) * | 1993-03-19 | 1993-03-19 | Novo Nordisk As | |
| DE69401583T2 (de) * | 1993-05-06 | 1997-06-12 | Novonordisk As | [1,2,4-TRIAZOLO[4,3-a]CHINOXALINVERBINDUNGEN DEREN HERSTELLUNG UND VERWENDUNG |
-
1995
- 1995-09-12 AU AU33808/95A patent/AU694554B2/en not_active Ceased
- 1995-09-12 WO PCT/DK1995/000365 patent/WO1996008493A1/fr not_active Application Discontinuation
- 1995-09-12 AT AT95930410T patent/ATE183186T1/de not_active IP Right Cessation
- 1995-09-12 CA CA002200056A patent/CA2200056A1/fr not_active Abandoned
- 1995-09-12 ES ES95930410T patent/ES2138233T3/es not_active Expired - Lifetime
- 1995-09-12 CN CN95195697A patent/CN1193973A/zh active Pending
- 1995-09-12 CZ CZ97753A patent/CZ284930B6/cs not_active IP Right Cessation
- 1995-09-12 TW TW084109492A patent/TW397835B/zh not_active IP Right Cessation
- 1995-09-12 KR KR1019970701669A patent/KR970706285A/ko not_active Application Discontinuation
- 1995-09-12 NZ NZ292108A patent/NZ292108A/xx unknown
- 1995-09-12 DE DE69511420T patent/DE69511420T2/de not_active Expired - Fee Related
- 1995-09-12 JP JP8509828A patent/JPH10506620A/ja active Pending
- 1995-09-12 SK SK334-97A patent/SK282457B6/sk unknown
- 1995-09-12 HU HU9701241A patent/HUT76802A/hu unknown
- 1995-09-12 EP EP95930410A patent/EP0781282B1/fr not_active Expired - Lifetime
- 1995-09-12 DK DK95930410T patent/DK0781282T3/da active
- 1995-09-12 PL PL95319175A patent/PL319175A1/xx unknown
- 1995-09-14 IL IL11529995A patent/IL115299A0/xx unknown
- 1995-09-15 ZA ZA957794A patent/ZA957794B/xx unknown
-
1997
- 1997-03-14 FI FI971076A patent/FI971076A/fi unknown
- 1997-03-14 NO NO971187A patent/NO308797B1/no not_active IP Right Cessation
-
1999
- 1999-11-09 GR GR990402881T patent/GR3031788T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU694554B2 (en) | 1998-07-23 |
| DE69511420T2 (de) | 2000-03-30 |
| FI971076A (fi) | 1997-05-13 |
| DK0781282T3 (da) | 2000-02-28 |
| TW397835B (en) | 2000-07-11 |
| CZ284930B6 (cs) | 1999-04-14 |
| IL115299A0 (en) | 1995-12-31 |
| NO308797B1 (no) | 2000-10-30 |
| ATE183186T1 (de) | 1999-08-15 |
| SK33497A3 (en) | 1998-02-04 |
| ES2138233T3 (es) | 2000-01-01 |
| NO971187L (no) | 1997-05-15 |
| NO971187D0 (no) | 1997-03-14 |
| FI971076A0 (fi) | 1997-03-14 |
| EP0781282A1 (fr) | 1997-07-02 |
| CA2200056A1 (fr) | 1996-03-21 |
| JPH10506620A (ja) | 1998-06-30 |
| PL319175A1 (en) | 1997-08-04 |
| ZA957794B (en) | 1996-05-14 |
| NZ292108A (en) | 1999-02-25 |
| GR3031788T3 (en) | 2000-02-29 |
| WO1996008493A1 (fr) | 1996-03-21 |
| CZ75397A3 (en) | 1997-08-13 |
| CN1193973A (zh) | 1998-09-23 |
| HUT76802A (en) | 1997-11-28 |
| KR970706285A (ko) | 1997-11-03 |
| DE69511420D1 (de) | 1999-09-16 |
| AU3380895A (en) | 1996-03-29 |
| EP0781282B1 (fr) | 1999-08-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5559106A (en) | Heterocyclic compounds, their use and preparation | |
| US5532236A (en) | [1,2,4]triazolo[4,3-a]quinoxaline compounds | |
| IL103160A (en) | Pharmaceuticals Containing 1,2,4 [Triazolo] -A] 4,3 Quinoxaline-4-Ones and 1,4Dions for the treatment of indications related to neurotransmitter overactivity | |
| SK282457B6 (sk) | [1,2,4]Triazolo[4,3-a]chinoxalinónové zlúčeniny, farmaceutický prostriedok, spôsob prípravy [1,2,4]triazolo[4,3-a]chinoxalinónových zlúčenín a ich použitie | |
| EP0743945B1 (fr) | Composes heterocycliques, leur preparation et leur utilisation | |
| SK282635B6 (sk) | [1,2,4]Triazolo[4,3-a]chinoxalinónové zlúčeniny, farmaceutický prostriedok, spôsob prípravy [1,2,4]triazolo[4,3-a] chinoxalinónových zlúčenín a ich použitie |